Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Net Cash Flow (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Net Cash Flow readings, the most recent being -$2.9 million for Q4 2023.

  • On a quarterly basis, Net Cash Flow fell 176.06% to -$2.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $5.9 million, a 460.94% increase, with the full-year FY2025 number at -$273000.0, down 105.28% from a year prior.
  • Net Cash Flow hit -$2.9 million in Q4 2023 for Elicio Therapeutics, up from -$5.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $95.9 million in Q1 2021 to a low of -$15.7 million in Q1 2022.
  • Median Net Cash Flow over the past 4 years was $2.6 million (2022), compared with a mean of $5.5 million.
  • The widest YoY moves for Net Cash Flow: up 2089.87% in 2021, down 410.17% in 2021.
  • Elicio Therapeutics' Net Cash Flow stood at $20.8 million in 2020, then plummeted by 167.33% to -$14.0 million in 2021, then soared by 127.19% to $3.8 million in 2022, then plummeted by 176.06% to -$2.9 million in 2023.
  • The last three reported values for Net Cash Flow were -$2.9 million (Q4 2023), -$5.2 million (Q3 2023), and $12.1 million (Q2 2023) per Business Quant data.